Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Aspire Health vs June Health

Aspire Health
Graded #346

Lower grade

vs+3.799999999999997
June Health
Graded #261

Higher grade

The verdict

June Health takes it — 63/100 to 59.2/100.

June Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. June Health is a direct-to-consumer telehealth storefront selling compounded GLP-1 medication for weight loss, alongside peptide, hormone, and hair-loss programs, all delivered online with no office visits.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueJune Health +16
45
61
Dose & formulationJune Health +22
53
75
Clinical oversightAspire Health +25
84
59
Labs & monitoringAspire Health +15
66
51
FulfillmentJune Health +13
61
74
Contract termsJune Health +14
41
55
Aspire Health · left barJune Health · right bar

The numbers

MetricAspire HealthJune Health
WeighScore59.2/10063/100
GradeCC
Scorecard rank#346#261
SemaglutideNot disclosed$179/mo (starting dose, compounded)
TirzepatideNot disclosed$179/mo (starting dose, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyYes
Aspire Health

Graded #346 · C

Strengths

  • Both compounded and brand-name options (Wegovy + Zepbound) — rare among GLP-1 telehealth providers
  • Lab orders with interpretation included in LoseIt membership — not billed separately
  • Named clinical team: founded by Jenni Haan, MPAS, PA-C (18+ years experience) with four additional credentialed providers
  • Slimpossible app + secure messaging for ongoing support between provider visits
  • HSA/FSA accepted; Cherry third-party financing available for patients needing payment plans

Where it loses points

  • Membership fee ($75/month) stacks on top of separately billed medication — total spend $205–$524/month depending on dose
  • No LegitScript certification or independent third-party accreditation disclosed
  • States served not publicly listed; availability depends on individual provider licensure
  • All medication sales are final once shipped; consultation fee non-refundable once completed
  • Compounding pharmacy partner not named on any public page
June Health

Graded #261 · C

Strengths

  • Offers both injectable and oral compounded semaglutide and tirzepatide
  • Semaglutide starts at $179/mo (injectable) or $187/mo (tablets) — tirzepatide from $179/mo (injectable)
  • Full per-dose price list published on-site with no signup required to view it
  • Provider consult ('licensed clinician evaluation') is bundled into the displayed price
  • Free discreet shipping advertised with 2-3 day delivery

Where it loses points

  • No accessible Terms of Service or Privacy Policy — footer links go nowhere and standard URL guesses 404
  • No LegitScript seal or other pharmacy-verification badge found anywhere on the site
  • Legal entity, prescribing medical group, and compounding pharmacy partner are not named
  • Domain was registered in May 2026 — a brand-new storefront with no independent reviews found
  • Also sells 'MR-3' (retatrutide), a GLP-1/GIP/glucagon agonist with no FDA approval for any use

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard